STARCOIN GROUP LIMITED
星 太 鏈 集 團 有 限 公 司

(Formerly known as Innovative Pharmaceutical Biotech Limited 領航醫藥及生物科技有限公司)

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock Code: 399)

SUPPLEMENTAL ANNOUNCEMENT
MEMORANDUM OF UNDERSTANDING FOR TOKEN ISSUE

Reference is made to the announcement of Starcoin Group Limited (the "**Company**") dated 13 October 2025 (the "**Announcement**") in relation to the memorandum of understanding dated 13 October 2025 in respect of the Token Issue. Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as defined in the Announcement.

The Company would like to supplement that in relation to the Token Issue, the Company will engage Hong Kong legal advisors specialised in digital assets to advise on the classification and structure of the Token Issue, including but not limited to the privacy considerations involved and the exclusion or alternative mechanisms for shareholders in jurisdictions where token distributions might be restricted. The Company will also engage distributors or agents with the relevant licenses to assist with the Token Issue if required. The Company will not proceed with the Token Issue unless and until it receives all necessary advices and confirmation that the arrangement for the Token Issue is in compliance with all applicable laws and regulations in all respects.

As at the date of this announcement, the Company is still in the course of carrying out legal review and consultation in respect of the Token Issue and has not commenced any consultation with the regulators. The Board will closely monitor the developments and any privacy or conflict of interest issues to ensure all governance procedures are duly and promptly complied with at all times.

Further announcement(s) will be made by the Company in compliance with the Listing Rules as and when appropriate and if there is any material development in this matter.

The above supplemental information does not affect other information contained in the Announcement and save as disclosed above, all other information set out in the Announcement remain unchanged.

GENERAL

The Token Issue is subject to the further negotiations between the Company and Starcoin Foundation and the Token Issue therefore may or may not proceed. The Company will publish an announcement in compliance with the Listing Rules as when and appropriate. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Starcoin Group Limited
Yeung Yung
Chairman

Hong Kong, 30 October 2025

As at the date of this announcement, the Board comprises, Dr. Yeung Yung (Chairman and executive Director), Mr. Gao Yuan Xing (executive Director), Mr. Tang Rong (executive Director), Ms. Qi Shujuan (executive Director), Dr. Long Fan (executive Director), Dr. Wu Ming (executive Director), Mr. Zhang Shen (executive Director), Mr. Zhang Yi (non-executive Director), Ms. Chen Weijun (independent non-executive Director), Mr. Wang Rongliang (independent non-executive Director), Mr. Chen Jinzhong (independent non-executive Director), Dr. Xia Tingkang, Tim (independent non-executive Director) and Ms. Sun Sizheng (independent non-executive Director).

Please also refer to the published version of this announcement on the Company's website: starcoingroup.com.